Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Diabetes 14 , 28 (2024)
Your doctor will prescribe the dose that provides the best weight-loss without causing side effects
Drug class: GIP/GLP-1/Glucagon receptor triagonist Route: Once-weekly subcutaneous injection Developer: Eli Lilly and Company Phase: Phase 3 (TRIUMPH program) Status: Investigational NOT TEY approved by FDA or EMA (despite what your online dealer told you ) Here's how it compares to the drugs most people already know: - Semaglutide (Ozempic/Wegovy): activates 1 receptor GLP-1 - Tirzepatide (Mounjaro/Zepbound): activates 2 receptors GLP-1 + GIP - Retatrutide: activates 3 receptors GLP-1 + GIP + Glucagon That third receptor the glucagon receptor is the differentiator
Activation of GLP-1R leads to an increase in intracellular cAMP and/or calcium, triggering signaling pathways including protein kinase A (PKA), exchange proteins directly activated by cAMP (Epac-2), phospholipase C (PLC), and extracellular signal-regulated kinase 1 and 2 (ERK1/2), thereby mediating effects on glycemic regulation, immune process, and inflammation
Immune IV package: Immune-supporting vitamins C, D and zinc combat infections
US$ 23.08
US$ 22.94
